Purified galactomannan as an improved pharmaceutical excipient
US6063402A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Jun 7, 1995 |
| Grant date | May 16, 2000 |
| Priority date | — |
| Expiry date | Jun 7, 2015 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC08L5/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed is a substantially anhydrous, powdered, galactomannan composition consisting essentially of a galactomannan hydrocolloid exhibiting about 50% to about 90% by weight of anhydromannose residues and about 10% to about 50% by weight anhydrogalactose residues; less than about 1% by weight of protein material and less than about 3% of other nonaqueous impurities. This material is useful for preparing pharmaceutical compositions both in the substantially anhydrous form but preferably in an anhydrated form which includes about 5-15% by weight water. The pharmaceutical compositions comprise a therapeutically effective amount of a drug, the hydrated powered gallactomannan composition and optionally other pharmaceutically-acceptable excipients. When the hydrated powdered purified glactomannan of the invention is used to form a tablet, one sees improved hardness in the tablet formed. The pharmaceutical composition of the invention is particularly valuable for delivering a therapeutically effective drug to the colon without significant release of the drug in the upper GI tract after oral administration of the composition. Unique means to prepare the purified galactomannan in large qua…
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.